The presence of TP53 mutations, the triple mutational combination DNMT3A/NPM1/FLT3-ITD, and the presence of MDS-related co-mutations and of high-risk chromosomic abnormalities are all conditions that shift NPM1-mut AML patients into an adverse-risk condition. This evidence concerns the gene NPM1 and acute myeloid leukemia.